The Pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania

Introduction

Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is the biggest challenge facing Tuberculosis (TB) care and treatment worldwide (1). MDR-TB is a major contributor to global antimicrobial resistance (AMR) and continues to pose a public health threat (1–3). MDR-TB is considered when there is resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs. The main problem is rifampicin resistance, the most potent first-line treatment (1). Patients with rifampicin-resistant TB or MDR-TB require a second-line treatment regimen (4). Globally, the annual estimated number of MDR-TB or rifampicin-resistant TB cases was steady between 2015 and 2020; however, it increased in 2021. In 2021, it was estimated to be 450,000 events, a 3.1% increase from 437,000 in 2020 (1).

The World Health Organization (WHO) developed a strategy to end TB-related deaths, illnesses, and suffering by 2035 (5). It recommends accelerating the identification and enhancing treatment for MDR-TB. Apart from access to diagnosis, adequate infection control must also be implemented in the settings where patients are treated (4). To diagnose MDR-TB, WHO recommends more specific and sensitive assays like real-time polymerase chain reaction (RT-PCR), DNA microarray, and loop-mediated isothermal amplification (LAMP). These technologies determine the mutations in the genes to identify drug resistance. In some populations of HIV-infected presumptive TB patients, the lateral flow lipoarabinomannan assay (LF-LAM) test is advised to aid in the diagnosis of TB (6).

The invention of the Xpert® MTB/RIF Assay (Cepheid, USA), which simultaneously detects the presence of Mycobacterium tuberculosis (MTB) and rifampicin resistance, has transformed the diagnosis of TB. Rifampicin inhibits DNA-directed RNA synthesis of MTB proteins by binding to the subunit of the bacterial DNA-dependent RNA polymerase (rpoB) enzyme. Rifampicin resistance has been associated with the rpoB gene mutation. Almost 96.1% of rifampicin-resistant MTB strains have rpoB mutations (7). The rifampicin resistance is the proxy sign of the MDR-TB (8,9). GeneXpert/MTB RIF is a cartridge-based, automated hemi-nested-nested real-time Polymerase Chain Reaction (PCR) system that utilizes five overlapping probes named Probe A (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523– 529) and Probe E (codons 529–533) (10).

Studies in Africa revealed that the commonest mutation of rpoB occurs at probes E and D (11–13). However, the literature shows different pattern distributions of the rpoB gene mutation of MTB associated with drug resistance (11–13). There is a need to determine whether the findings in other studies apply to our setting due to the varied findings obtained in various geographical areas. No other study has been conducted in Tanzania to reveal the patterns of rpoB mutation. Due to efforts to increase access to GeneXpert MTB/RIF diagnosis in the country, there is also a need to determine the factors associated with Rifampicin-resistant TB.

Methods

Results

We extracted data for 112,768 nonrepeating patients tested for TB using GeneXpert. Of all, 56,662 (50.2%) had laboratory-confirmed TB. Rifampicin resistance was identified in 450/56,662 (0.8%) patients with MTB. The specific gene mutations in the rpoB gene of Mycobacterium tuberculosis were identified in the form of the missing probes, which indicated a specific mutation occurs at a specific codon in the rpoB gene named Probe A (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523–529), and Probe E (codons 529–533). Missing probes (specific rpoB mutation detected) were found in 219/ 450 (48.7%) samples with Rifampicin-resistant MTB, and no missing probes (no specific rpoB mutation detected) in 231/450 (51.3%) with Rifampicin-resistant. Rif Indeterminate were observed in 658/56,662 (1.16%) of patients with MTB and were excluded in further analysis (Fig 1).

• Download figure
• Open in new tab

Fig 1. Flow chart of participants’ analysis

Demographic and clinical characteristics of study participants

A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them, 38,705/56,004 (69.11%) were male. The age group 35-44 years accounted for the largest cases, 13,512/56,004 (24.13%). Most participants, 55,192/56,004 (98.55%), had pulmonary TB. Participants with new TB were 53,818/56,004 (96.1%), and 45,016/56,004 (80.38%) were HIV-negative (Table 1). The Dar es Salaam region contributed 10,524/56,004 (18.79%) cases, which is higher than in any other region. The lowest number of cases were reported from the Katavi region. The regional distribution of cases is shown in Fig 2.

• Download figure
• Open in new tab

Fig 2. Map showing the proportion distribution of study participants per region

View this table:

• View inline
• View popup

Table 1. Participants’ demographic and clinical characteristics (N=56,004)

Discussion

The current study found that the most prevalent mutation in rpoB gene mutation in MTB was at probe E codon (529–533) (40.64%), followed by Probe D codon (523–529) 20.09% which was similar to studies done in Nigeria, Uganda, Pakistan, Addis Ababa Ethiopia, and Bangladesh (13–17), the similarities suggests that a significant number of low-income individuals migrating for shelters may be responsible for the spread of mutant strains within the community (18). Our findings differed from the study done in Northeast India and Enugu, South Eastern Nigeria, which revealed that the most prevalent mutations were detected at probes A and D, respectively (19,20). The differences might be attributed to geographical differences caused by the variations in the M. tuberculosis lineage (21). According to the results of our study and previous studies, probe E is linked to the most common probe mutation in the rpoB gene mutation.

The study found that new TB patients had a significantly higher number of specific rpoB mutations not detected among those with rifampicin resistance than previously treated patients. Our finding is similar to a Northeast India study (20). This may result from an early stage of TB diagnosis, which may have a low bacillary load. No missing probe may also be triggered by various probes having varying target hybridization dynamics, which might have a higher impact after extended PCR cycles (22). Patients with low TB bacillary load also had more no-missing probes. This could mean GeneXpert testing in patients with less advanced disease and lower bacterial density (new patients) is considered less accurate in detecting rifampicin-resistant tuberculosis (23). The very low bacillary load on GeneXpert testing was shown to be substantially linked to false rifampicin resistance during the initial GeneXpert assay (22). The samples with very low bacillary load were not retested; hence, the rate of false positives for rifampicin resistance could not be determined.

The rifampicin resistance was found more in patients with both pulmonary and extra-pulmonary TB than in pulmonary or extra-pulmonary alone. In addition, patients with both pulmonary and extra-pulmonary TB had almost four times greater odds of developing rifampicin resistance. Our findings were comparable to the study done in the Debre Markos Referral Hospital Ethiopia (24). We also found that previously treated patients had significantly higher rifampicin resistance than new patients. The likelihood of rifampicin resistance was nearly nine times higher in previously treated patients than in new patients, similar to the study done in Nepal (25). Our findings support that MTB increases the ability to develop resistance when exposed to anti-TB drugs, especially in patients with poor adherence to treatment (26). In our study, the odds of developing rifampicin resistance in previously treated patients were higher than in Somalia and other East Gojjam zone northwest Ethiopia studies, which revealed four and six times, respectively (27,28).

HIV-positive TB patients had a higher gene mutation than HIV-negative. HIV-positive individuals had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals; this was similar to the studies done in northwest Ethiopia (27,29). Variations in TB/HIV co-infection have been reported in several studies, indicating challenges in diagnosis and treatment due to unusual clinical presentations and difficulties in diagnosis and treatment (30–32). This may be due to differences in TB control strategies and approaches (29). More rifampicin-resistant MTB in HIV patients might be caused by poor treatment adherence. Poor adherence to treatment is the primary factor contributing to drug resistance (25,31). This highlights the need for more surveillance and community involvement.

The study had limitations, including missing variables and being unable to confirm false positive rates for rifampicin resistance at low bacillary load. However, the large sample size of participants from all Tanzania mainland regions made the findings representative and generalisable to all regions.

Conclusion

The rate of rifampicin resistance in our study was low compared to other studies done in Tanzania. The Probe E (codons 529–533)-related mutations were the most prevalent rpoB gene mutation. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB are associated with rifampicin resistance. The findings highlight the need to strengthen the surveillance of MDR-TB among patients identified with a higher risk of rifampicin resistance.

Ethical considerations

Ethical approval was obtained from the MUHAS Senate Research and Publications Committee of Muhimbili University of Health and Allied Sciences, Ref. No. DA.282/298/01L/629. Approval to use the national TB program data was obtained from the NTLP Program Manager in the Ministry of Health (MoH). The data was routinely collected by health facilities providing TB care and treatment services in which ethical issues are strongly advocated.

Author contributions

PRT, AJ, HK, MVM and LU authors contributed equally to the design. PRT, MRM, MCM, SSN, RMK, CF, RB, PS and JK did data collection and write-up of this manuscript. AJ and MVM reviewed the manuscript. All authors read and approved the final manuscript.